Related Experiment Video

Updated: Oct 19, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.5K

Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools

Sébastien Verdickt1, Bart Van der Schueren1,2, Roman Vangoitsenhoven1,2

  • 1Department of Diabetes and Endocrinology, University Hospitals of Leuven, Leuven, Belgium.

International Journal of Clinical Practice
|September 22, 2021
PubMed

Insights

Alirocumab, a PCSK9 inhibitor, effectively lowers LDL-c in high-risk Belgian patients. This non-statin therapy is crucial for achieving lipid targets when statins alone are insufficient.

Area of Science:

  • Cardiology
  • Pharmacology
  • Genetics

Background:

  • Stringent lipid targets in ESC/EAS guidelines leave many patients above goal on statin monotherapy.
  • This highlights the need for effective add-on lipid-lowering therapies.
  • Alirocumab, a PCSK9 inhibitor, was evaluated in high cardiovascular risk patients.

Purpose of the Study:

  • To analyze the characteristics, safety, and efficacy of alirocumab in the Belgian ODYSSEY APPRISE trial cohort.
  • To evaluate the importance and necessity of add-on non-statin lipid-lowering therapy in clinical practice based on literature.
  • To assess alirocumab's role in achieving guideline-directed lipid targets.

Main Methods:

  • Prospective, single-arm, open-label, multicentric Phase 3b trial (ODYSSEY APPRISE).
  • 68 Belgian patients enrolled, with 63 having heterozygous familial hypercholesterolaemia (HeFH).
  • Evaluated LDL-c reduction and treatment-emergent adverse events (TEAEs) at 12 weeks.

Main Results:

  • Mean baseline LDL-c was 188.7 mg/dL.
  • A 59.9% mean LDL-c reduction was observed at 12 weeks in 65 evaluable patients.
  • Overall TEAE incidence was 75.0%, with common events including back pain, nasopharyngitis, and injection site erythema.

Conclusions:

  • Alirocumab demonstrated good tolerability, safety, and significant LDL-c reduction in the Belgian cohort within a real-world setting.
  • Add-on non-statin therapy like alirocumab is essential for patients to reach their risk-based lipid targets.
  • Clinical practice should increase initiation of alirocumab to improve lipid management.
Abstract

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.7K
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.4K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
67
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
968
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
401
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.2K